Patents by Inventor Stephen Neidle
Stephen Neidle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230212166Abstract: The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers.Type: ApplicationFiled: December 27, 2022Publication date: July 6, 2023Inventors: Stephen Neidle, Richard Angell, Sally Oxenford
-
Patent number: 11560380Abstract: The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers. The NDIs are a compound of Formula I.Type: GrantFiled: May 15, 2020Date of Patent: January 24, 2023Assignee: UCL Business LtdInventors: Stephen Neidle, Richard Angell, Sally Oxenford
-
Publication number: 20220220108Abstract: The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers.Type: ApplicationFiled: May 15, 2020Publication date: July 14, 2022Inventors: Stephen NEIDLE, Richard ANGELL, Sally OXENFORD
-
Publication number: 20190330197Abstract: A compound comprising the formula I that has DNA-quadruplex binding and stabilising activity and potential in treatment of pancreatic and other human cancers.Type: ApplicationFiled: December 14, 2016Publication date: October 31, 2019Inventors: Stephen Neidle, Chiara Marchetti, Stephan Alexander Ohnmacht
-
Patent number: 9493460Abstract: The invention relates to novel compounds which are naphthalene diimides of general formula (I): The compounds are used in therapy, particularly in cancer treatment.Type: GrantFiled: March 13, 2013Date of Patent: November 15, 2016Assignee: UCL BUSINESS PLCInventors: Stephen Neidle, Stephan A. Ohnmacht, Mekala Gunaratnam, Aaron Grainger Dale, Marialuisa Micco, Gavin William Collie
-
Patent number: 9145377Abstract: A compound of formula I wherein Ar1 is a bicyclic aryl or heteroaryl, which may be optionally substituted; X and Y are each independently a group of formula II: -L1-Ar2-L2-Ar3-Q-(CH2)n-NR1R2 L1 and L2 are each independently selected from NR3, C2H2, CH2, —O—, —S— and a bond; Ar2 and Ar3 are independently optionally substituted C5 or C6 aryl or heteroaryl; Q is selected from NH(C?O), NR3, S, O; n is an integer from 1 to 5; R1 and R2 are optionally substituted and are independently hydrogen, C1-7 alkyl, C3-20 heterocyclyl, or C5-20 aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; R3 is H or C1-7 alkyl.Type: GrantFiled: April 4, 2012Date of Patent: September 29, 2015Assignee: University College LondonInventors: Stephen Neidle, Caterina Maria Lombardo, Sarah Welsh
-
Publication number: 20140275062Abstract: The invention relates to novel compounds which are naphthalene diimides of general formula (I): The compounds are used in therapy, particularly in cancer treatment.Type: ApplicationFiled: March 13, 2013Publication date: September 18, 2014Inventors: Stephen NEIDLE, Stephan A. OHNMACHT, Mekala GUNARATNAM, Aaron Grainger DALE, Marialuisa MICCO, Gavin William COLLIE
-
Patent number: 8796456Abstract: The invention relates to novel compounds which are naphthalene diimides of general formula (I). The compounds are used in therapy, particularly in cancer treatment.Type: GrantFiled: November 28, 2008Date of Patent: August 5, 2014Assignee: University College LondonInventors: Mekala Gunaratnam, Francisco Cuenca, Stephen Neidle
-
Publication number: 20140107168Abstract: A compound of formula I wherein Ar1 is a bicyclic aryl or heteroaryl, which may be optionally substituted; X and Y are each independently a group of formula II: -L1-Ar2-L2-Ar3-Q-(CH2)n-NR1R2 L1 and L2 are each independently selected from NR3, C2H2, CH2, —O—, —S— and a bond; Ar2 and Ar3 are independently optionally substituted C5 or C6 aryl or heteroaryl; Q is selected from NH(C?O), NR3, S, O; n is an integer from 1 to 5; R1 and R2 are optionally substituted and are independently hydrogen, C1-7 alkyl, C3-20 heterocyclyl, or C5-20 aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; R3 is H or C1-7 alkyl.Type: ApplicationFiled: April 4, 2012Publication date: April 17, 2014Applicant: UNIVERSITY COLLEGE LONDONInventors: Stephen Neidle, Caterina Lombardo, Sarah Walsh
-
Publication number: 20100311739Abstract: The invention relates to novel compounds which are naphthalene diimides of general formula (I). The compounds are used in therapy, particularly in cancer treatment.Type: ApplicationFiled: November 28, 2008Publication date: December 9, 2010Inventors: Mekala Gunaratnam, Francisco Cuenca, Stephen Neidle
-
Publication number: 20080319001Abstract: The present invention relates to a 3,6,9 acridine compound and optionally substituted derivatives thereof that may be useful in the treatment of cancer. The invention also provides compositions comprising the compounds and uses thereof. Formula (I) wherein each of R1, R2, R3, R4 and R5 is either fluorine or is not present (i.e. represents a hydrogen atom); n represents 1 or 2.Type: ApplicationFiled: March 2, 2006Publication date: December 25, 2008Inventors: Christina Martins, Stephen Neidle, Mekala Gunaratnam, John Stuart, Lloyd Kelland
-
Patent number: 7312082Abstract: The present invention relates to a crystal structure of G-quadruplexes and its use. The invention provides a crystal of an intramolecular G-quadruplex structure having a hexagonal space group P6, and unit cell dimensions a=b=56.7 and c=42.1; ?=?=90°, ?=120° and a crystal of G-quadruplex having the three dimensional atomic coordinates of Table 1 or Table 2. These structures may be used in a computer-based method for the analysis of the interaction of a molecular structure with a G-quadruplex.Type: GrantFiled: April 2, 2003Date of Patent: December 25, 2007Assignee: Cancer Research Technology LimitedInventors: Stephen Neidle, Gary N. Parkinson
-
Patent number: 7300930Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ?O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptablType: GrantFiled: June 22, 2005Date of Patent: November 27, 2007Assignee: Cancer Research Technology LimitedInventors: Stephen Neidle, Richard John Harrison, Lloyd Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka
-
Patent number: 7205311Abstract: This invention pertains to certain acridone and acridine compounds of the formula which inhibit telomerase, regulate cell proliferation, etc., and/or treat cancer, proliferative conditions, etc.Type: GrantFiled: January 14, 2003Date of Patent: April 17, 2007Assignee: Cancer Research Technology LimitedInventors: Stephen Neidle, Richard John Harrison, Lloyd Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka
-
Patent number: 7160896Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ?O, L is —H, alpha single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptable salType: GrantFiled: July 6, 2001Date of Patent: January 9, 2007Assignee: Cancer Research Technology LimitedInventors: Stephen Neidle, Richard John Harrison, Lloyd Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reskza
-
Publication number: 20060111389Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ?O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones): or, (b) K is a 9-substituent. L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen.Type: ApplicationFiled: June 22, 2005Publication date: May 25, 2006Applicant: Cancer Research Technology LimitedInventors: Stephen Neidle, Richard Harrison, Lloyd Kelland, Sharon Gowan, Martin Read, Anthony Reszka
-
Publication number: 20050070568Abstract: This invention pertains to certain acridine and acridine compounds of the formula (1) which inhibit telomerase, regulate cell proliteration, etc., and/or treat cancer proliferative conditions, etc.Type: ApplicationFiled: January 14, 2003Publication date: March 31, 2005Inventors: Stephen Neidle, Richard Harrison, Lloyd Kelland, Sharon Gowan, Martin Read, Anthony Reszka
-
Publication number: 20040018483Abstract: The present invention relates to a crystal structure of G-quadruplexes and its use. The invention provides a crystal of an intramolecular G-quadruplex structure having a hexagonal space group P6, and unit cell dimensions a=b=56.7 and c=42.1; &agr;=&bgr;=90°, &ggr;=120° and a crystal of G-quadruplex having the three dimensional atomic coordinates of Table 1 or Table 2. These structures may be used in a computer-based method for the analysis of the interaction of a molecular structure with a G-quadruplex.Type: ApplicationFiled: April 2, 2003Publication date: January 29, 2004Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Stephen Neidle, Gary N. Parkinson, Michael Pak Ho Lee
-
Publication number: 20030207909Abstract: The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent.Type: ApplicationFiled: April 4, 2003Publication date: November 6, 2003Inventors: Stephen Neidle, Richard John Harrison, Llyod Royston Kelland, Sharon Michele Gowan, Martin Anthony Read, Anthony Reszka
-
Patent number: 6589971Abstract: “Head-to-head” bis-benzimidazoles having the following formula wherein A1, A2, X1 and X2 are as defined in the following specification, have been found to bind to specific sequences in the minor groove of duplex DNA, and to have cytotoxic effects against a range of tumor cell lines.Type: GrantFiled: April 18, 2002Date of Patent: July 8, 2003Assignees: The Queens University of Belfast, Institute of Cancer Research, The University of ReadingInventors: Stephen Neidle, John Monn